Summary:
The purpose of this study is to assess the efficacy of intranasal esketamine plus an oral antidepressant compared with an oral antidepressant (active comparator) plus intranasal placebo in delaying relapse of depressive symptoms in participants with treatment-resistant depression (TRD) who are in stable remission after an induction and optimization course of intranasal esketamine plus an oral antidepressant.
Qualified Participants Must:
• Be between 18 and 64 years of age (Adult)
•
Be diagnosed with depression
Qualified Participants May Receive:
Study-related medical care and investigational drug at no cost and may be compensated for time and travel.